A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

Trial Profile

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 13 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 21 Jul 2017 This trial has been discontinued in Poland (End date: 2017-05-09)
    • 20 Jul 2017 This trial has been discontinued in Spain (End date: 2017-05-09)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top